|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/436 | |
| A61K 31/519 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2558092 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11715370.0 |
| Europos patento paraiškos padavimo data | 2011-04-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-02-20 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-06-27 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/032062 |
| Data | 2011-04-12 |
| (87) | Numeris | WO 2011/130232 |
| Data | 2011-10-20 |
| (30) | Numeris | Data | Šalis |
| 323541 P | 2010-04-13 | US |
| (72) |
BORLAND, Maria, US
BRAIN, Christopher Thomas, US
DOSHI, Shivang, US
KIM, Sunkyu, US
MA, Jianguo, US
MURTIE, Josh, US
ZHANG, Hong, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE 6 (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER |
| COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE 6 (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER |